Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Syndax Launches Revuforj® for Relapsed/Refractory Acute Leukemia Treatment
Syndax Pharmaceuticals has launched Revuforj® (revumenib), the first and only menin inhibitor for treating relapsed or refractory (R/R) acute leukaemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and paediatric patients aged one year and older....
Johnson & Johnson Unveils First and Only Nipocalimab for the Treatment of Sjögren’s disease
Johnson & Johnson has introduced nipocalimab as the first investigational therapy for adults with moderate-to-severe Sjögren’s disease (SjD), a chronic autoimmune condition affecting approximately four million people globally, predominantly women....
Fresenius Kabi Launches Tyenne®, the First Tocilizumab Biosimilar
Fresenius Kabi has launched its tocilizumab biosimilar, Tyenne®, which references Actemra®** (tocilizumab), making it the first and only tocilizumab biosimilar available in Canada....
Hansoh Pharmaceutical Group Introduces Breakthrough B7-H3-Targeted Antibody-Drug Conjugate (ADC) HS-20093
Hansoh Pharmaceutical Group has announced that its B7-H3-targeted antibody-drug conjugate (ADC), HS-20093, has received approval for breakthrough therapy designation from the National Medical Products Administration (NMPA) of China. ...
Ultragenyx Pharmaceutical Developed First-of-its-kind Setrusumab (UX143) for Osteogenesis Imperfecta
Ultragenyx Pharmaceutical has developed setrusumab (UX143), a groundbreaking treatment aimed at reducing the fracture risk associated with osteogenesis imperfecta (OI) Types I, III, or IV in patients aged 2 years and older....
Boehringer Ingelheim Discovered Novel Survodutide for the Treatment of Advanced Fibrosis
Boehringer Ingelheim has identified a novel treatment known as survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist, for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis (stages 2 or 3)....
Arrowhead Pharmaceuticals Develops Novel Plozasiran
Arrowhead Pharmaceuticals has developed plozasiran (formerly ARO-APOC3), a novel investigational therapy designed to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). ...
Genentech Unveils First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech has unveiled Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), making it the first and only PD-(L)1 inhibitor available as a subcutaneous (SC) injection in the United States....
Johnson & Johnson Develops Novel RYBREVANT® for EGFR-Mutated Advanced Lung Cancer
Johnson & Johnson has introduced a groundbreaking therapy, RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib), for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or exon 21 L858R substitution mutations....
Daiichi Sankyo Introduces First-of-its-kind ENHERTU® for Metastatic Breast Cancer
Daiichi Sankyo has introduced ENHERTU®, a groundbreaking treatment option for certain patients with HER2 low or HER2 ultralow metastatic breast cancer. ENHERTU is a leading antibody-drug conjugate (ADC) in oncology portfolio, designed using proprietary DXd ADC technology....
